首页> 外文期刊>Briefings in bioinformatics >Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes
【24h】

Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes

机译:优先考虑癌症基因组中驱动程序突变和显着突变的基因的计算方法的进展

获取原文
获取原文并翻译 | 示例
           

摘要

Cancer is often driven by the accumulation of genetic alterations, including single nucleotide variants, small insertions or deletions, gene fusions, copy-number variations, and large chromosomal rearrangements. Recent advances in next-generation sequencing technologies have helped investigators generate massive amounts of cancer genomic data and catalog somatic mutations in both common and rare cancer types. So far, the somatic mutation landscapes and signatures of > 10 major cancer types have been reported; however, pinpointing driver mutations and cancer genes from millions of available cancer somatic mutations remains a monumental challenge. To tackle this important task, many methods and computational tools have been developed during the past several years and, thus, a review of its advances is urgently needed. Here, we first summarize the main features of these methods and tools for whole-exome, whole-genome and whole-transcriptome sequencing data. Then, we discuss major challenges like tumor intra-heterogeneity, tumor sample saturation and functionality of synonymous mutations in cancer, all of which may result in false-positive discoveries. Finally, we highlight new directions in studying regulatory roles of noncoding somatic mutations and quantitatively measuring circulating tumor DNA in cancer. This review may help investigators find an appropriate tool for detecting potential driver or actionable mutations in rapidly emerging precision cancer medicine.
机译:癌症通常是由遗传改变的累积驱动的,包括单核苷酸变异,小的插入或缺失,基因融合,拷贝数变异和大的染色体重排。下一代测序技术的最新进展已帮助研究人员生成了大量癌症基因组数据,并分类了常见和罕见癌症类型的体细胞突变。到目前为止,已经报道了> 10种主要癌症类型的体细胞突变情况和特征;然而,从数百万个可用的癌症体细胞突变中找出驱动程序突变和癌症基因仍然是一个巨大的挑战。为了解决这一重要任务,在过去几年中已经开发了许多方法和计算工具,因此,迫切需要对其进展进行回顾。在这里,我们首先总结用于全外显子组,全基因组和全转录组测序数据的这些方法和工具的主要特征。然后,我们讨论了诸如肿瘤内异质性,肿瘤样品饱和度以及癌症同义突变的功能等主要挑战,所有这些挑战均可能导致假阳性发现。最后,我们着重指出了研究非编码体细胞突变的调控作用以及定量测量癌症中循环肿瘤DNA的新方向。这项审查可能有助于研究人员找到合适的工具,以检测快速发展的精密癌症药物中的潜在驱动因素或可操作的突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号